Status:
COMPLETED
Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
Lead Sponsor:
AIO-Studien-gGmbH
Collaborating Sponsors:
Prof. Hartmut Link
MMF GmbH
Conditions:
Anemia, Iron Deficiency
Solid Tumor
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to analyze the implementation of the 2018 updated ESMO Guideline in patients with tumor diseases as well as the corre-sponding recommendations of the Onkopedia Guideline and th...
Detailed Description
Health care structure analysis and recruitment (phase 1): In a first step, data on care facilities treating patients in the above indica-tions in Germany will be collected (gastroenterology, gynecolo...
Eligibility Criteria
Inclusion
- Patients
- with antineoplastic therapy (chemotherapy or "new substances"), radiochemotherapy or radiotherapy in the period 1/1/2021 - 06/30/2021
- with anemia with hemoglobin levels decreases below 10g/dl (6.2 mmol/l) at least once during the period 1/1/2021 - 06/30/2021
- with at least 4 weeks of follow up period after anemia diagnosis.
Exclusion
- Follow up time less than 4 weeks,
- lack of patient contact after anemia diagnosis
Key Trial Info
Start Date :
October 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 6 2022
Estimated Enrollment :
1053 Patients enrolled
Trial Details
Trial ID
NCT05190263
Start Date
October 25 2021
End Date
February 6 2022
Last Update
February 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Studienzentrum Prof. Dr. med. Hartmut Link, Facharzt für Innere Medizin, Hämatologie und Internistische Onkologie
Kaiserslautern, Germany, 67661